Cargando…

Prognostic importance of IDH mutations in chondrosarcoma: An individual patient data meta‐analysis

INTRODUCTION: IDH1/2 mutations are prevalent in cartilaginous tumors including chondrosarcoma. This meta‐analysis using individual patient data (IPD) aimed to investigate the clinical and prognostic association of these mutations in chondrosarcoma patients. METHODS: Two electronic databases includin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vuong, Huy Gia, Ngo, Tam N.M., Dunn, Ian F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267117/ https://www.ncbi.nlm.nih.gov/pubmed/34085407 http://dx.doi.org/10.1002/cam4.4019

Ejemplares similares

Incidence, Prognostic Factors, and Survival Trend in Pineal Gland Tumors: A Population-Based Analysis
por: Vuong, Huy Gia, et al.
Publicado: (2021)

IDH Mutations in Chondrosarcoma: Case Closed or Not?
por: Venneker, Sanne, et al.
Publicado: (2023)

The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: a meta-analysis
por: Vuong, Huy Gia, et al.
Publicado: (2020)

IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
por: Lugowska, Iwona, et al.
Publicado: (2018)

Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation
por: Peterse, Elisabeth F. P., et al.
Publicado: (2018)

Beyond the Influence of IDH Mutations: Exploring Epigenetic Vulnerabilities in Chondrosarcoma
por: Venneker, Sanne, et al.
Publicado: (2020)

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution
por: Rodriguez, Erika F., et al.
Publicado: (2020)

Prognostic nomograms to predict overall survival and cancer‐specific survival in patients with pelvic chondrosarcoma
por: Chen, Li, et al.
Publicado: (2019)

Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection
por: Gutteridge, Alice, et al.
Publicado: (2017)

Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
por: Venneker, Sanne, et al.
Publicado: (2019)

Long‐term outcomes of primary cardiac malignant tumors: Difference between African American and Caucasian population
por: Bui, Quoc, et al.
Publicado: (2021)

Clonality analysis and IDH1 and IDH2 mutation detection in both components of dedifferentiated chondrosarcoma, implicated its monoclonal origin
por: Yang, Tingting, et al.
Publicado: (2020)

Multiregional radiomics profiling from multiparametric MRI: Identifying an imaging predictor of IDH1 mutation status in glioblastoma
por: Li, Zhi‐Cheng, et al.
Publicado: (2018)

Prognostic Implication of Patient Age in H3K27M-Mutant Midline Gliomas
por: Vuong, Huy Gia, et al.
Publicado: (2022)

IMMUNOHISTOCHEMICAL ANALYSIS BY KI67 AND IDH1 IN PATIENTS WITH CHONDROSARCOMA
por: RIBEIRO, MARCELO BARBOSA, et al.
Publicado: (2023)

Distinct IDH1/2-associated Methylation Profile and Enrichment of TP53 and TERT Mutations Distinguish Dedifferentiated Chondrosarcoma from Conventional Chondrosarcoma
por: Dermawan, Josephine Kam Tai, et al.
Publicado: (2023)

The prognostic impact of subclonal IDH1 mutation in grade 2–4 astrocytomas
por: Vij, Meenakshi, et al.
Publicado: (2023)

Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis
por: de Botton, Stéphane, et al.
Publicado: (2021)

IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience
por: Setola, Elisabetta, et al.
Publicado: (2023)

Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma
por: Ma, Sirui, et al.
Publicado: (2020)

Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth
por: Li, Luyuan, et al.
Publicado: (2020)

Mutant IDH and non-mutant chondrosarcomas display distinct cellular metabolomes
por: Pathmanapan, Sinthu, et al.
Publicado: (2021)

Clinical usefulness of 2-hydroxyglutarate as a biomarker in IDH-mutant chondrosarcoma
por: Nakagawa, Makoto, et al.
Publicado: (2022)

Genetic alterations of differentiated thyroid carcinoma in iodine‐rich and iodine‐deficient countries
por: Vuong, Huy Gia, et al.
Publicado: (2016)

The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population‐based retrospective study
por: Ebied, Amr, et al.
Publicado: (2018)

IDH1 Mutation Induces HIF-1α and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells
por: Hu, Xiaoyu, et al.
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Prognostic Factors and Treatment Options for Patients with High-Grade Chondrosarcoma
por: Gao, Zhongyang, et al.
Publicado: (2019)

Circulating tumour DNA is a promising biomarker for risk stratification of central chondrosarcoma with IDH1/2 and GNAS mutations
por: Lyskjær, Iben, et al.
Publicado: (2021)

Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH‐wildtype glioblastoma
por: Funakoshi, Yusuke, et al.
Publicado: (2021)

Prognostic value of neutrophil‐to‐lymphocyte ratio and platelet‐to‐lymphocyte ratio for breast cancer patients: An updated meta‐analysis of 17079 individuals
por: Guo, Wanying, et al.
Publicado: (2019)

IDH1 Mutation in Gliomas in Mosul City - Iraq
por: Saeed, Mohammed Sami
Publicado: (2015)

Pharmacoresistant seizures and IDH mutation in low-grade gliomas
por: Correia, Carlos Eduardo, et al.
Publicado: (2021)

Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH-wildtype anaplastic astrocytomas: an institutional experience
por: Cho, Uiju, et al.
Publicado: (2021)

A meta-analysis of prognostic roles of molecular markers in papillary thyroid carcinoma
por: Vuong, Huy Gia, et al.
Publicado: (2017)

Isocitrate Dehydrogenase IDH1 and IDH2 Mutations in Human Cancer: Prognostic Implications for Gliomas
por: Murugan, A. K., et al.
Publicado: (2022)

Isocitrate dehydrogenase 1 mutations (IDH1) and p16/CDKN2A copy number change in conventional chondrosarcomas
por: Amary, M. Fernanda, et al.
Publicado: (2014)

Maffucci syndrome complicated by giant chondrosarcoma in the left ankle with an IDH1 R132C mutation: a case report
por: Lv, Haiyan, et al.
Publicado: (2022)

IDH Mutations: Genotype-Phenotype Correlation and Prognostic Impact
por: Wang, Xiao-Wei, et al.
Publicado: (2014)

Prognostic role of IDH mutations in gliomas: a meta-analysis of 55 observational studies
por: Xia, Liang, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_99jhr1iji2ussvgl1asam47la7